ALK and lung carcinoma: While our retrospective biomarker analysis was fairly comprehensive, it is limited due to several factors, including that many lung cancers were diagnosed before molecular testing for biomarkers, such as EGFR, ALK, ROS1 and others, were considered standard of care.